Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2024; 30(14): 1941-1948
Published online Apr 14, 2024. doi: 10.3748/wjg.v30.i14.1941
Immune checkpoint inhibitor-associated gastritis: Patterns and management
Jing Lin, Zhong-Qiao Lin, Shi-Cheng Zheng, Yu Chen
Jing Lin, Yu Chen, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350000, Fujian Province, China
Zhong-Qiao Lin, Phase I Clinical Trial Ward, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350000, Fujian Province, China
Shi-Cheng Zheng, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350000, Fujian Province, China
Co-first authors: Jing Lin and Zhong-Qiao Lin.
Author contributions: Lin J and Lin ZQ contributed equally to this work; Lin J designed the study and revised the manuscript; Lin ZQ performed the research and wrote the manuscript; Zheng SC wrote the manuscript and contributed on funding; Chen Y revised and supervised the manuscript, and contributed on funding; All authors have read and approve the final manuscript.
Supported by Joint Funds for the Innovation of Science and Technology, Fujian Province, China, No. 2021Y9227; Natural Science Foundation of Fujian Province, China, No. 2023J011254; The Science Foundation for The Excellent Youth Scholars of Fujian Provincial Health Commission, China, No. 2022ZQNZD009; The Special Research Funds for Local Science and Technology Development Guided by Central Government, Fujian Province, China, No. 2023L3020; and Fujian Medical University Student Innovation and Entrepreneurship Training Project, China, No. JC2023191.
Conflict-of-interest statement: All authors have no conflicts of interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu Chen, MD, Chief Doctor, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fumu Road, Jin’an District, Fuzhou 350000, Fujian Province, China. chenyu1980@fjmu.edu.cn
Received: December 15, 2023
Peer-review started: December 15, 2023
First decision: February 19, 2024
Revised: February 23, 2024
Accepted: March 28, 2024
Article in press: March 28, 2024
Published online: April 14, 2024
Core Tip

Core Tip: Immune checkpoint inhibitor (ICI)-related gastritis is rare but may lead to serious complications such as gastrorrhagia. Biopsy under esophagogastroduodenoscopy is the gold standard for diagnosis. Specifically, this article discusses strategies for treating ICI-related gastritis, including early recognition, pathological diagnosis, management interventions, and rechallenge with immunotherapy, providing clinicians with valuable consultations to enable cancer patients to benefit early from treatment.